Summary

Other Scenarios:

Buyer: Eisai Co., Ltd (ADR) (ESALY) Last Price: 34.00 Market Cap.: 9.66B
Target: Pharmion Corporation (PHRM) Last Price: 72.32 Market Cap.: 2.71B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
Healthcare 918
Biopharmaceuticals 375

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 37)
  • Fragmin (Dalteparin Sodium)
  • E5555 (Thrombin Receptor Agonist)
  • MGi Pharma GPI21016 (Poly ADP-Ribose Polymerase (PARP) Inhibitor)
  • Ontak (Denileukin Diftitox)
Target (Total: 5)
  • Innohep (Tinzaparin Sodium)
  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Oral Azacitidine
  • Vidaza (Azacitidine)
Buyer

n/a
Target

n/a

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 5)
  • TorreyPines Therapeutics Inc. (TPTX)
  • Eurand N.V. (EURX)
  • ZymoGenetics, Inc. (ZGEN)
  • Pharsight Corporation (PHST)
Target (Total: 6)
  • GPC Biotech AG (ADR) (GPCB)
  • Celgene Corporation (CELG)
  • salesforce.com, inc. (CRM)
  • MethylGene Inc. (MYG:CA)
Buyer (Total: 3)
  • Bristol Myers Squibb Co. (BMY)
  • McKesson Corporation (MCK)
  • AmerisourceBergen Corp. (ABC)
Target (Total: 4)
  • US Oncology, Inc.
  • Cardinal Health, Inc. (CAH)
  • McKesson Corporation (MCK)
  • Government - United Kingdom

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 9,649 513
Revenue Per Employee 794,107.0 558,770.6
Total Revenue 5,238.5 71.5
Total Expenses 4,364.8 102.6
Other Revenue 0.0 0.0
Cost of Revenue 782.9 19.7
SG&A Expense 2,658.0 50.0
Research & Development 932.2 30.4
Other Operating Expense -0.9 0.0
Operating Income 873.7 -31.2
Unusual Income -7.4 0.0
LT Debt to Capital 0 0
Fwd P/E 13.89 -395.28
Fwd P/Rev 1.40 7.21
Book Value 5,355.3 358.9
Curr Portion of LTD/Cap Lease 0.0 0.0

Individual Company Summary

Focused

Buyer

Focused (): Healthcare > Biopharmaceuticals > Neurology

Target

Focused (): Healthcare > Biopharmaceuticals > Oncology

Business Description

Buyer

Eisai Co., Ltd. is a Japan-based company mainly engaged in the manufacturing and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacturing and sale of drugs for pharmaceutical, over-the-counter and diagnostic uses. The Others segment offers food additives, chemicals and medicine manufacturing equipment. Headquartered in Tokyo, Eisai has 45 subsidiaries and one associated company in the country, as well as in North America, Europe and Asia. In January 2008, the Company completed the acquisition of MGI PHARMA, INC. As a result of the acquisition, MGI PHARMA becomes a wholly owned subsidiary of Eisai Corporation of North America.

Target

Pharmion Corporation is a global pharmaceutical company that acquires, develops and commercializes products for the treatment of hematology and oncology patients. The Company has established a portfolio of approved products and product candidates focused on the hematology and oncology markets. These include Pharmion?s primary commercial products, Vidaza (azacitidine for injection), which it markets and sells as an approved treatment for myelodysplastic syndromes in the United States, Switzerland, Israel and the Philippines. and Thalidomide Pharmion 50 milligram (Thalidomide Pharmion), a therapy for the treatment of multiple myeloma and certain other forms of cancer, which it sells on a compassionate use or named patient basis in certain countries of Europe. Thalidomide Pharmion is approved in Australia, New Zealand, Turkey, Israel, South Korea and Thailand for the treatment of multiple myeloma. In January 2008, Celgene Corporation has cleared its pending acquisition of Pharmion.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 84.56 72.66
Operating Margin % 15.47 -25.91
Quick Ratio 1.65 3.64
Current Ratio 2.19 4
Coverage Ratio 0.09 -0.15
Total Assets 7,523.0 443.3
Return on Equity % 13.83 -17.79
Return on Assets % 9.55 -14.4
Cash+ ST Inv. Per Share 4.9 6.67
Total Debt 0.0 0.0
Total Debt to Equity % 0 0
Total Debt to Tangible Equity % 0 0
Debt to Asset % 0.00 0.00

Product Summary

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
  
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
  
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
Transplantation
The Transplantation Subsectors includes therapeutics that treat rejection and infection associated with tissue transplantation into the human body.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
Healthcare
Biopharmaceuticals
Cardiovascular System
Heart Disorders  
Angina  
Anticoagulating Agents  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Fragmin (Dalteparin Sodium)
  
Myocardial Infarction (MI)  
Anticoagulating Agents  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Fragmin (Dalteparin Sodium)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • E5555 (Thrombin Receptor Agonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • MGi Pharma GPI21016 (Poly ADP-Ribose Polymerase (PARP) Inhibitor)
  
Vascular Disorders
Deep Vein Thrombosis (DVT)
Anticoagulating Agents (Anticoagulants)
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Buyer Products:

  • Fragmin (Dalteparin Sodium)

Target Products:

  • Innohep (Tinzaparin Sodium)
Thromboembolism
Anticoagulating Agents (Anticoagulants)
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Fragmin (Dalteparin Sodium)

Target Products:

  • Innohep (Tinzaparin Sodium)
Dermatology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Ontak (Denileukin Diftitox)
  • Targretin Capsules (Bexarotene)
  • Targretin Gel (Bexarotene)
  
Digestive System  
Gastrointestinal Tract Disorders  
Gastroduodenal Disorders  
Peptic Ulcers  
Duodenal  
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Aciphex (Rabeprazole)
  
Gastric  
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Aciphex (Rabeprazole)
  
Zollinger-Ellison Syndrome  
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Aciphex (Rabeprazole)
  
Gastroesophageal Disorders  
Gastroesophageal Reflux Disease (GERD)  
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Aciphex (Rabeprazole)
  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.

Buyer Products:

  • MGi Pharma Aloxi (Palonosetron)
  • MGi Pharma Oral Aloxi (Palonosetron)
  
Stomatognathic Disorders  
Mucositis  
Immunomodulatory Agents
Therapeutics that treat mucositis by stimulating the immune system.

Buyer Products:

  • MGi Pharma Saforis (L-Glutamine)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Aciphex (Rabeprazole)
  
Endocrinology/Metabolism  
Diabetes  
Induced Complications  
Diabetic Neuropathy  
Aldose Reductase Inhibitors
Therapeutics that treat diabetic neuropathy by stopping the action of the enzyme involved in changing glucose to alcohol.

Buyer Products:

  • AS-3201 (Ranirestat)
  
Hematology
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Target Products:

  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Oral Azacitidine
  
White Blood Cell (WBC) Disorders
Myelodysplastic Syndromes (MDS)
Antimetabolite Agents
Pyrimidine Analogs
Therapeutics that treat and manage rmyelodysplastic syndrome by interfering with the production of DNA.

Buyer Products:

  • MGi Pharma Dacogen (Decitabine)

Target Products:

  • Vidaza (Azacitidine)
Immunology  
Autoimmune Disorders  
Sjogren`s Syndrome  
Palliative Agents  
Cholinergic Agents
Therapeutics that treat the symptoms of a chronic systemic inflammatory disorder characterized by progressive dryness of mucous membranes by stimulating saliva production.

Buyer Products:

  • MGi Pharma Salagen (Pilocarpine Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • E2007 (AMPA Receptor Antagonist)
  • Ontak (Denileukin Diftitox)
  • Targretin Capsules (Bexarotene)
  • Targretin Gel (Bexarotene)
  • MGi Pharma AKR-501 (Thrombopoietin Mimetic)
  
Infectious Diseases  
Bacterial  
Antibacterial Agents  
Narrow Spectrum  
Digestive System  
Heliobacter pylori  
Proton Pump Inhibitors
Therapeutics treat digestive infections caused by Helicobacter pylori bacteria by inhibiting the action of the membrane protein involved in the final steps of triggering acid release into the stomach.

Buyer Products:

  • Aciphex (Rabeprazole)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • E5564 (Eritoran)
  
Sepsis  
Toll-Like Receptor Antagonists
Therapeutics that treat sepsis by to blocking the effects of endotoxin of Gram-negative bacteria.

Buyer Products:

  • E5564 (Eritoran)
  
Neurology  
Neurological Disorders  
Alzheimer`s Disease  
Acetylcholinesterase Inhibitors
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine.

Buyer Products:

  • Aricept (Donepezil Hydrochloride)
  
Dementia  
Acetylcholinesterase Inhibitors
Therapeutics that treat dementia by preventing the breakdown of a the neurotransmitter, acetylcholine.

Buyer Products:

  • Aricept (Donepezil Hydrochloride)
  
Epilepsy  
Partial Seizures  
Complex  
Adjunctive Therapy  
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.

Buyer Products:

  • Inovelon (Rufinamide)
  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.

Buyer Products:

  • Zonegran (Zonisamide)
  
Simple  
Adjunctive Therapy  
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.

Buyer Products:

  • Zonegran (Zonisamide)
  
Status Epilepticus  
Sodium Channel Modulators
Therapeutics that treat Status Epilepticus by modulating the portal that allows sodium into the nerve cells.

Buyer Products:

  • Cerebyx (Fosphenytoin Sodium)
  
Neuromuscular Disorders  
Parkinson`s Disease (PD)  
Monotherapy  
AMPA Receptor Antagonists
Therapeutics that treat the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by inhibiting the binding of glutamate to AMPA Receptors.

Buyer Products:

  • E2007 (AMPA Receptor Antagonist)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Aricept (Donepezil Hydrochloride)
  • TVP-1012 (Rasagiline Mesylate)
  • E2007 (AMPA Receptor Antagonist)
  • E2012 (Gamma Secretase Modulator)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • BAN2401 (Monoclonal Antibody)
  • MGi Pharma GPC II Inhibitors
  
Obstetrics/Gynecology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • MGi Pharma Amolimogene Bepiplasmid (DNA Based Immunostimulant - Formerly ZYC101a)
  
Oncology
Breast Cancer  
Metastatic  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • E7389 (Antimicrotubule Agent)
  
Dermatology  
Kaposi`s Sarcoma  
Retinoids/Vitamin A Analogs
Therapeutics that treat and manage cancers of spindle cells by helping in cell differentiation as well as decreasing proliferation of cells.

Buyer Products:

  • Panretin Gel (Alitretinoin)
  
Head/Neck Cancer  
Palliative Agents  
Cholinergic Agents
Therapeutics that treat dry mouth resulting from radiotherapy for cancer of the head and neck.

Buyer Products:

  • MGi Pharma Salagen (Pilocarpine Hydrochloride)
  
Hematology  
Leukemia (White Blood Cell Cancer)  
Myeloid  
Acute  
Myelogenous (AML)  
Antimetabolite Agents  
Pyrimidine Analogs
Analogs of the pyrimidine bases of nucleic acids that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting the production of DNA.

Buyer Products:

  • MGi Pharma Dacogen (Decitabine)
  
Lymphoma (Lymphatic Cancer)  
Cutaneous T-Cell (CTCL)  
Mycosis Fungoides  
Interleukin-2 (IL-2) Receptor-Targeted Cytotoxins (Fusion Proteins)
Therapeutics that treat and manage T-cell lymphomas by specifically binding onto the surface of the cancer cells and inhibiting protein synthesis, leading to apoptosis (cell death).

Buyer Products:

  • Ontak (Denileukin Diftitox)
  
Retinoids/Vitamin A Analogs
Therapeutics that treat and manage T-Cell lymphomas of the skin by interfering with protein synthesis.

Buyer Products:

  • Targretin Capsules (Bexarotene)
  • Targretin Gel (Bexarotene)
  
Neurology  
Brain Cancer  
Glioma  
Glioblastoma  
Alkylating Agents  
Nitrosoureas
Therapeutics that can cross the blood-brain barrier to treat and manage tumors of the glial cells by interacting with DNA and inhibiting cell division.

Buyer Products:

  • MGi Pharma Gliadel Wafer (Polifeprosan 20 With Carmustine Implant)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • Panretin Capsules (Alitretinoin)
  • MGi Pharma Irofulven (Hydroxymethylacylfulvene)
  • Targretin Capsules (Bexarotene)
  • MGi Pharma Dacogen (Decitabine)
  • Ontak (Denileukin Diftitox)
  • E7070 (Sulfonamide)
  • E7974 (Antimicrotubule Agent)
  • E7080 (VEGF Inhibitor)
  • MGi Pharma ZYC300 (DNA Based Immunostimulant)
  • E7820
  • E7389 (Antimicrotubule Agent)

Target Products:

  • MGCD0103 (Histone Deacetylase (HDAC) Inhibitor)
  • Vidaza (Azacitidine)
  • Oral Azacitidine
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • Targretin Capsules (Bexarotene)
  • MGi Pharma GPI21016 (Poly ADP-Ribose Polymerase (PARP) Inhibitor)
  
Respiratory System/Thoracic
Lung Cancer
Non Small Cell Lung Cancer (NSCLC)  
Retinoids/Vitamin A Analogs
Therapeutics that treat and manage lung cancer by activating the retinoid X receptors. These receptors function as transcription factors for the expression of genes responsible for cell differentiation and proliferation.

Buyer Products:

  • Targretin Capsules (Bexarotene)
  
Small Cell Lung Cancer (SCLC)  
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the small cells in the lung by inhibiting a specific enzyme, topoisomerase II, needed for transcription and replication of DNA.

Target Products:

  • Amrubicin (Anthracycline)
  
Urology  
Ovarian Cancer  
Palliative Agents  
DNA Synthesis Inhibitors
Therapeutics that treat and manage ovarian cancer by inhibiting the synthesis of DNA but are not curative.

Buyer Products:

  • MGi Pharma Hexalen (Altretamine)
  
Pain Management  
Anesthesia  
General (Systemic)  
Primary  
Hypnotic Agents (Sedatives)
Therapeutics that result in anesthesia by inducing sleep. These therapeutics have no analgesic action.

Buyer Products:

  • MGi Pharma AQUAVAN Injection (Propofol)
  
Surgery
Musculoskeletal System
Deep Vein Thrombosis (DVT)
Anticoagulating Agents (Anticoagulants)
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Buyer Products:

  • Fragmin (Dalteparin Sodium)

Target Products:

  • Innohep (Tinzaparin Sodium)
Neurology  
Seizures  
Sodium Channel Modulators
Therapeutics that treat seizures by controlling the entrance of sodium into the nerve cells.

Buyer Products:

  • Cerebyx (Fosphenytoin Sodium)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of surgical complications in early stages of clinical research where human subject is involved.

Buyer Products:

  • E5564 (Eritoran)
  
Transplantation  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the management of rejection and infection in early stages of clinical research where human subject is involved.

Buyer Products:

  • Ontak (Denileukin Diftitox)
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  GlaxoSmithKline plc (ADR) n/a 115,986.006 11.18 10.85 2.57 2.53 15.20
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Vion Pharmaceuticals, Inc. n/a 25.897 0.00 -0.71 1,194.74 n/a 3.14
Buyer
  GlaxoSmithKline plc (ADR) n/a 115,986.006 11.18 10.85 2.57 2.53 15.20
Schering-Plough Corporation n/a 32,021.742 0.00 13.35 2.52 1.78 72.12
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Shire plc (ADR) n/a 11,013.064 0.00 19.66 4.52 3.82 n/a
Pharmion Corporation n/a 2,706.069 0.00 -395.28 10.12 7.21 10.58
DURECT Corporation n/a 350.289 0.00 -14.88 11.42 11.63 12.51
Idera Pharmaceuticals, Inc. n/a 216.791 0.00 -12.85 27.16 25.01 28.09
Targacept , Inc. n/a 162.964 0.00 -5.30 14.08 9.32 3.16
Generex Biotechnology Corporation n/a 123.244 0.00 n/a 1,400.00 n/a 4.77
Peregrine Pharmaceuticals n/a 113.105 0.00 n/a 18.45 n/a 4.12
Santarus, Inc. n/a 97.499 0.00 -4.30 1.03 0.81 6.35
Target
  Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
GlaxoSmithKline plc (ADR) n/a 115,986.006 11.18 10.85 2.57 2.53 15.20
sanofi-aventis (ADR) n/a 98,531.811 16.69 9.14 2.25 2.40 n/a
Genentech, Inc. n/a 83,607.511 30.19 25.16 7.13 6.43 9.13
Eli Lilly & Co. n/a 56,508.154 19.14 12.64 3.03 2.79 5.04
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Eisai Co., Ltd (ADR) n/a 9,661.528 13.56 13.89 1.46 1.40 2.29
Millennium Pharmaceuticals, Inc. n/a 4,249.041 284.76 58.61 8.05 7.65 5.90
SuperGen, Inc. n/a 135.648 10.37 -12.63 5.91 3.71 1.48
Poniard Pharmaceuticals, Inc. n/a 132.393 0.00 -3.07 n/a 12.14 1.53
Vion Pharmaceuticals, Inc. n/a 25.897 0.00 -0.71 1,194.74 n/a 3.14

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  TorreyPines Therapeutics Inc. 100.00% 25.496 0.00 -1.35 2.59 2.75 0.83
Eurand N.V. 6.00% 591.051 0.00 35.29 4.54 3.65 n/a
ZymoGenetics, Inc. n/a 616.269 0.00 -4.97 16.02 8.02 5.37
Pharsight Corporation n/a 44.598 0.00 29.56 1.59 1.58 5.07
MultiCell Technologies, Inc. n/a 1.151 0.00 n/a 5.22 n/a n/a
Target
  GPC Biotech AG (ADR) 66.00% 123.561 0.00 -1.04 3.95 3.84 1.63
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
salesforce.com, inc. n/a 6,759.538 368.29 174.97 9.03 6.62 16.14
MethylGene Inc. n/a 87.304 0.00 n/a 6.00 n/a 1.75
Ben Venue Laboratories, Inc. n/a n/a n/a n/a n/a n/a n/a
Ash Stevens, Inc. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  McKesson Corporation n/a 16,575.105 17.63 17.42 0.17 0.16 5.60
Buyer
  Bristol Myers Squibb Co. n/a 43,309.011 20.00 12.88 2.24 2.02 10.23
McKesson Corporation n/a 16,575.105 17.63 17.42 0.17 0.16 5.60
AmerisourceBergen Corp. n/a 6,687.985 14.64 14.03 0.10 0.10 n/a
Target
  US Oncology, Inc. 19.00% n/a n/a n/a n/a n/a n/a
Cardinal Health, Inc. 11.00% 19,851.610 12.83 14.65 0.22 0.21 15.33
McKesson Corporation 9.00% 16,575.105 17.63 17.42 0.17 0.16 5.60
Government - United Kingdom n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Buyer
  Johnson & Johnson n/a 174,233.403 16.47 14.11 2.85 2.79 11.97
Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
GlaxoSmithKline plc (ADR) n/a 115,986.006 11.18 10.85 2.57 2.53 15.20
Novartis AG (ADR) n/a 108,444.656 9.08 13.48 2.78 2.71 3.88
Abbott Laboratories n/a 78,894.465 21.88 16.18 3.04 2.85 40.89
3M Company n/a 54,143.275 13.22 14.28 2.21 2.09 8.52
Teva Pharmaceutical Industries Ltd (ADR) n/a 38,602.146 19.78 17.88 4.10 3.61 11.36
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Solvay S.A. (ADR) n/a 10,334.385 9.01 n/a 0.73 n/a n/a
Elan Corporation, plc (ADR) n/a 9,306.151 0.00 -51.95 12.25 9.50 n/a
Sepracor Inc. n/a 2,099.453 35.99 12.73 1.71 1.66 11.93
Target
  Pfizer Inc. n/a 144,347.120 17.73 9.11 2.98 3.03 6.24
Celgene Corporation n/a 22,917.366 101.21 38.96 16.30 11.48 8.45
Cardinal Health, Inc. n/a 19,851.610 12.83 14.65 0.22 0.21 15.33
McKesson Corporation n/a 16,575.105 17.63 17.42 0.17 0.16 5.60
GPC Biotech AG (ADR) n/a 123.561 0.00 -1.04 3.95 3.84 1.63
MethylGene Inc. n/a 87.304 0.00 n/a 6.00 n/a 1.75
US Oncology, Inc. n/a n/a n/a n/a n/a n/a n/a
LEO Pharma A/S n/a n/a n/a n/a n/a n/a n/a
Ash Stevens, Inc. n/a n/a n/a n/a n/a n/a n/a
Dainippon Sumitomo Pharma Co., Ltd. n/a n/a n/a n/a n/a n/a n/a
Ben Venue Laboratories, Inc. n/a n/a n/a n/a n/a n/a n/a
Nippon Shinyaku Co., Ltd. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 6,602.0 267.3 6,869.3
Other Revenue 0.0 0.0 0.0
Total Revenue 6,602.0 267.3 6,869.3
Cost of Revenue 1,019.4 73.1 1,092.5
SG&A Expense 3,349.1 143.2 3,492.3
Depreciation & Amortization 94.6 9.9 104.5
Research & Development 1,103.2 102.4 1,205.5
Interest Expense 0.0 0.0 0.0
Other Operating Expense -1.1 0.0 -1.1
Unusual Expense (Income) 15.2 8.0 23.2
Total Expenses 5,580.4 336.5 5,916.9
Operating Income 1,021.6 -69.2 952.4
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng 87.1 10.2 97.2
Gain/Loss On Sale Of Assets -5.1 0.0 -5.1
Other, Net -1.7 0.0 -1.7
Income Before Taxes 1,101.8 -59.1 1,042.8
Income Taxes 383.2 4.8 387.9
Income After Taxes 718.7 -63.9 654.8
Minority Interest (IS) -6.0 0.0 -6.0
Net Income - Excl. Xord. Items 712.7 -63.9 648.9
Net Income - Incl. Xord. Items 712.7 -63.9 648.9
Misc. Earnings Adjustment -0.0 0.0 -0.0
Income Avail. to Common 712.7 -63.9 648.9
Share Items
Basic Avg. Shares Outstanding 284.1 37.3 321.4
Basic EPS - Excl. Xord. Items 2.51 n/a 2.02
Basic EPS - Incl. Xord. Items 2.51 n/a 2.02
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 284.5 37.3 321.7
F.D. EPS - Excl. Xord. Items 2.51 n/a 2.02
F.D. EPS - Incl. Xord. Items 2.51 n/a 2.02
Dividends Per Common Share 1.20 0.00 1.20
Balance Sheet
Assets
Cash and Equivalents 615.7 178.9 794.6
ST Investments 778.1 69.7 847.8
Accounts Receivable 1,525.8 45.0 1,570.7
Inventory 491.7 12.8 504.5
Prepayments and Advances 0.0 2.8 2.8
Other Current Assets 461.0 13.6 474.6
Current Assets 3,872.2 322.8 4,195.0
PPE 266.7 0.0 266.7
Accum D&A 0.0 0.0 0.0
PPE, Net 998.3 11.4 1,009.7
Goodwill & Intangibles 1,119.1 103.1 1,222.2
Long Term Investments 813.2 0.0 813.2
Other Assets 0.0 0.0 0.0
Other LT Assets 453.4 6.0 459.4
Total Assets 7,523.0 443.3 7,966.3
Liabilities
Accounts Payable 159.1 14.3 173.4
Payable/Accrued 0.0 0.0 0.0
Accrued Expenses 693.8 66.3 760.2
ST Debt 0.0 0.0 0.0
Other (Current) Liabilities 911.6 0.0 911.6
Current Liab. 1,764.5 80.6 1,845.1
LT Debt 0.0 0.0 0.0
Total LT Debt 0.0 0.0 0.0
Minority Interest (BS) 94.6 0.0 94.6
Deferred Taxes 154.4 2.7 157.1
Other LT Liab. 312.6 1.1 313.7
Total Liabilities 2,326.1 84.4 2,410.4
Shareholders Equity
Common Stock 413.9 0.0 413.9
Additional Paid in Capital 513.2 631.7 1,144.9
Retained Earnings 4,515.9 -290.7 4,225.2
Unrealized Gain (Loss) 114.4 0.0 114.4
Treasure Stock -387.6 0.0 -387.6
Other Equity 27.1 17.9 45.0
Total Equity 5,196.9 358.9 5,555.8
Total Liab. & Equity 7,523.0 443.3 7,966.3
Shares Outstanding 284.2 37.4 321.5
Cash Flow
Operating Cash Flow
CF Net Income 489.5 -63.9 425.7
CF Depreciation 143.9 12.6 156.5
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items -73.1 3.2 -69.9
Change in Working Capital 118.6 24.5 143.1
Total Cash From Operating Activities 678.9 -23.5 655.4
Investing Cash Flow (not calculated)
Capital Expenditures 42.9 -6.7 36.2
Other Investing Cash Flows -132.8 8.6 -124.3
Total Cash From Investing Activities -89.9 1.8 -88.1
Financing Cash Flow (not calculated)
Dividends Paid 0.0 0.0 0.0
Purchase Or Sale of Stock 0.0 138.0 138.0
Purchase and Retirement of Debt -2.3 -0.9 -3.2
Other Financing Cash Flow 2.4 0.4 2.8
Total Cash From Financing Activities 0.1 137.5 137.6
Exchange Rate Effects -58.6 3.2 -55.4
Net Change in Cash 530.6 119.0 649.6
Cash Taxes Paid 83.3 3.0 86.3
Cash Interest Paid 0.6 0.2 0.7